Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation

Systemic sclerosis (SSc) is a progressive, multi-organ disease with limited treatment options. While a recent proof-of-concept study using Romilkimab or SAR156597, a bi-specific IL-4/IL-13 antibody, suggests a direct role of these cytokines in the pathophysiology of SSc, their contributions to the b...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American journal of respiratory cell and molecular biology 2023-10, Vol.69 (4), p.404-421
Hauptverfasser:	Mattoo, Hamid, Bangari, Dinesh S, Cummings, Sheila, Humulock, Zachary, Habiel, David, Xu, Ethan Y, Pate, Nathan, Resnick, Robert, Savova, Virginia, Qian, George, Beil, Christian, Rao, Ercole, Nestle, Frank O, Bryce, Paul J, Subramaniam, Arun
Format:	Artikel
Sprache:	eng
Schlagworte:	Bispecific antibodies Cytokines Fibrosis Inflammation Interleukin 13 Interleukin 4 Lung diseases Lymphocytes T Pulmonary fibrosis Scleroderma Systemic sclerosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!